Literature DB >> 7558821

[Lindane].

C Surber1, T Rufli.   

Abstract

In Europe and in the US ectoparasitic diseases are increasingly diagnosed in all classes of society. Modern means of transportation promote the spreading from endemic areas into new regions and therefore questions of therapy are becoming increasingly important. A series of preparations in various galenic formulations and in various concentrations are available to treat the ectoparasitic diseases. Due to reports on Lindane poisonings the clinical use of Lindane preparations for the treatment of scabies and pediculosis has become somewhat controversial. In this article we review older and more recent data on pharmacology, pharmacokinetics and toxicology of gamma-1,2,3,4,5,6-Hexachlorcyclohexan [Lindane]. It is pointed out that in the USA Lindane is offered in 1% preparations whereas in the German speaking Europe only 0.3% preparations are available. This latter concentration is considered as sufficient to treat the ectoparasitosis. Furthermore the use of this remedy and aspects of Lindane resistance are discussed. It is concluded that only through additional in depth education of the patients and their folks successful treatment is possible and intoxication can be prevented.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7558821     DOI: 10.1007/s001050050294

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  3 in total

Review 1.  Pharmacotherapy of ectoparasitic infections.

Authors:  T C Roos; M Alam; S Roos; H F Merk; D R Bickers
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Prevention and treatment of head lice in children.

Authors:  K Y Mumcuoglu
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

3.  Protection by conventional and new antiepileptic drugs against lindane-induced seizures and lethal effects in mice.

Authors:  A M Tochman; R Kamiński; W A Turski; S J Czuczwar
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.